Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Aiman Waheed, MBBS
Advertisement
Articles by Aiman Waheed, MBBS
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
Advertisement
Latest Updated Articles
Efficacy and Safety of Zolbetuximab in Gastric CancerDecember 6th 2024
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
5